As of May 25
| +0.25 / +0.73%|
The 21 analysts offering 12-month price forecasts for Pfizer have a median target of 38.00, with a high estimate of 54.00 and a low estimate of 33.00. The median estimate represents a +10.63% increase from the last price of 34.35.
The current consensus among 24 polled investment analysts is to Buy stock in Pfizer. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.